Das G, et al. - The intention of the researchers was to gauge the safety profile of rituximab therapy prior to and during pregnancy in women with multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSDs) who could be at risk of relapses. Rituximab treatment did not display any major safety signal within 6 months of conception. A total of 78 pregnancies resulted in live births in the review analysis and 10 out of 11 pregnancies in term live births of healthy newborns in the case series analysis.